## Do you have Eosinophilic Granulomatosis with Polyangiitis (EGPA – Churg Strauss Syndrome)?



Are you taking a daily, high dose of corticosteriods, such as prednisone or prednisolone?

And are you interested in taking part in a clinical trial to test a new treatment?

AstraZeneca is looking for people with EGPA to take part in a clinical trial called MANDARA¹.

**MANDARA** will be investigating whether an investigational product is safe and can provide benefit to people with EGPA.

## Who can join?

MANDARA may be suitable for you if you:



Are aged 18 years or older



Have been diagnosed with EGPA for at least 6 months



Have been experiencing EGPA symptoms, despite being treated with high doses of corticosteroids such as prednisolone of more than 7.5 mg per day

## Why participate?

The findings of this study will be used to help develop new EGPA treatments.

If you are eligible to take part, you:

Date: 23-08-2021



Will receive expert medical care, related to the study, at no cost to you



May receive compensation, relating to time and travel costs



Will help make a difference for people diagnosed with EGPA in the future

If you are interested in taking part in the MANDARA study, please speak with your doctor today.

Email: information.center@astrazeneca.com

Phone: 1-877-240-9479 www.mandarastudy.com

